Assessment of the Phototoxic Potential of LEO 29102 Cream
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: LEO 29102 cream
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 32
- Registration Number
- NCT00958516
- Locations
- 🇫🇷
LEO Pharma investigational site, St Quentin en Yvelines Cedex, France
LEO 29102 Single and Multiple Dose Study by Dermal Application
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 64
- Registration Number
- NCT00891709
- Locations
- 🇬🇧
LCG Bioscience, Bourn, Cambridgeshire, United Kingdom
A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products
- Conditions
- Psoriasis Vulgaris
- Interventions
- Drug: Daivobet® OintmentDrug: LEO 29102 Cream VehicleDrug: LEO 29102 creamDrug: LEO 29102 Plus Calcipotriol Cream
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT00875277
- Locations
- 🇫🇷
LEO Pharma site, Saint-Quentin-en-Yvelines, France
Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
- Conditions
- Papulopustular Rosacea
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 207
- Registration Number
- NCT00855595
A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris
- Conditions
- Psoriasis Vulgaris
- Interventions
- Drug: Daivobet® ointmentDrug: Betnovat® ointmentDrug: Dermovat ointmentDrug: Daivobet® ointment vehicle
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT00845481
- Locations
- 🇫🇷
LEO Pharma Investigational Site, Saint Quentin Yvelines Cedex, France
LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 58
- Registration Number
- NCT00833872
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
- Conditions
- Psoriasis Vulgaris
- Interventions
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 33
- Registration Number
- NCT00817219
- Locations
- 🇺🇸
Center for Dermatology Clinical Research, Fremont, California, United States
🇺🇸University of California at San Diego/Rady Children's Hospital, San Diego, California, United States
🇺🇸Northwestern University's Feinberg School of Medicine, Chicago, Illinois, United States
Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
- Conditions
- Psoriasis Vulgaris
- Interventions
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 51
- Registration Number
- NCT00764751
- Locations
- 🇨🇦
UltraNova Skincare, Barrie, Ontario, Canada
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
- Conditions
- Secondarily Infected Traumatic Lesions (SITL)Impetigo
- Interventions
- Drug: 2% TD1414 Cream
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT00758862
- Locations
- 🇺🇸
J&S Studies, Inc., College Station, Texas, United States
Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy
- Conditions
- Acute Lung InjuryAcute Respiratory Distress Syndrome
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 418
- Registration Number
- NCT00742482
- Locations
- 🇳🇴
Ullevål University Hospital, INtensive Care Department, Oslo, Norway
🇧🇪Erasme University Hospital, Brussels, Belgium
🇳🇱Academisch Medisch Centrum, Amsterdam, Netherlands